Literature DB >> 30143809

[Current treatment of systemic scleroderma].

Nicolas Hunzelmann1.   

Abstract

Systemic sclerosis (scleroderma) is a severe, chronic inflammatory connective tissue disease involving the skin, musculoskeletal system, and several internal organs. The heterogeneity of its presentation and course are a particular challenge for the treating physician. As therapeutic options have improved considerably during recent years, various working groups have published consensus recommendations for the treatment of SSc. The aim of this overview is to present major aspects of these recommendations and embed them in a concept of modern interdisciplinary care for this often still devastating disease.

Entities:  

Keywords:  Connective tissue diseases; Fibrosis; Organ involvement; Pharmacological therapy; Systemic sclerosis

Mesh:

Year:  2018        PMID: 30143809     DOI: 10.1007/s00105-018-4258-7

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  30 in total

1.  Low-dose UVA1 phototherapy in systemic sclerosis: effects on acrosclerosis.

Authors:  Alexander Kreuter; Frank Breuckmann; Andrea Uhle; Norbert Brockmeyer; Gregor Von Kobyletzki; Marcus Freitag; Markus Stuecker; Klaus Hoffmann; Thilo Gambichler; Peter Altmeyer
Journal:  J Am Acad Dermatol       Date:  2004-05       Impact factor: 11.527

Review 2.  [Management of digital ulcers in patients with systemic sclerosis].

Authors:  G Riemekasten; U Hoffmann; C Sunderkötter; N Weiss; A Kuhn
Journal:  Dtsch Med Wochenschr       Date:  2011-12-16       Impact factor: 0.628

3.  European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes.

Authors:  R Knobler; P Moinzadeh; N Hunzelmann; A Kreuter; A Cozzio; L Mouthon; M Cutolo; F Rongioletti; C P Denton; L Rudnicka; L A Frasin; V Smith; A Gabrielli; E Aberer; M Bagot; G Bali; J Bouaziz; A Braae Olesen; I Foeldvari; C Frances; A Jalili; U Just; V Kähäri; S Kárpáti; K Kofoed; D Krasowska; M Olszewska; C Orteu; J Panelius; A Parodi; A Petit; P Quaglino; A Ranki; J M Sanchez Schmidt; J Seneschal; A Skrok; M Sticherling; C Sunderkötter; A Taieb; A Tanew; P Wolf; M Worm; N J Wutte; T Krieg
Journal:  J Eur Acad Dermatol Venereol       Date:  2017-08-09       Impact factor: 6.166

4.  Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial.

Authors:  F H van den Hoogen; A M Boerbooms; A J Swaak; J J Rasker; H J van Lier; L B van de Putte
Journal:  Br J Rheumatol       Date:  1996-04

5.  Gastrointestinal Manifestations of Systemic Sclerosis.

Authors:  Andrew B Shreiner; Charles Murray; Christopher Denton; Dinesh Khanna
Journal:  J Scleroderma Relat Disord       Date:  2016-10-18

6.  EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).

Authors:  O Kowal-Bielecka; R Landewé; J Avouac; S Chwiesko; I Miniati; L Czirjak; P Clements; C Denton; D Farge; K Fligelstone; I Földvari; D E Furst; U Müller-Ladner; J Seibold; R M Silver; K Takehara; B Garay Toth; A Tyndall; G Valentini; F van den Hoogen; F Wigley; F Zulian; Marco Matucci-Cerinic
Journal:  Ann Rheum Dis       Date:  2009-01-15       Impact factor: 19.103

Review 7.  Scleroderma lung disease.

Authors:  Joshua J Solomon; Amy L Olson; Aryeh Fischer; Todd Bull; Kevin K Brown; Ganesh Raghu
Journal:  Eur Respir Rev       Date:  2013-03-01

8.  Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study.

Authors:  F M Wigley; R A Wise; J R Seibold; D A McCloskey; G Kujala; T A Medsger; V D Steen; J Varga; S Jimenez; M Mayes; P J Clements; S R Weiner; J Porter; M Ellman; C Wise; L D Kaufman; J Williams; W Dole
Journal:  Ann Intern Med       Date:  1994-02-01       Impact factor: 25.391

Review 9.  [Iloprost therapy in systemic sclerosis].

Authors:  G Bali; E Aberer
Journal:  Hautarzt       Date:  2003-09       Impact factor: 0.751

Review 10.  Scleroderma renal crisis.

Authors:  Luc Mouthon; Guillaume Bussone; Alice Berezné; Laure-Hélène Noël; Loïc Guillevin
Journal:  J Rheumatol       Date:  2014-05-15       Impact factor: 4.666

View more
  2 in total

Review 1.  [The skin and rheumatism].

Authors:  S Ständer; R J Ludwig; D Thaçi
Journal:  Orthopade       Date:  2019-11       Impact factor: 1.087

2.  Elastography as a possible useful method of assessment of skin involvement in systemic sclerosis.

Authors:  Piotr Sobolewski; Monika Dźwigała; Jakub Zakrzewski; Łukasz Paluch; Jacek Bogucki; Elżbieta Szymañska; Irena Walecka
Journal:  Postepy Dermatol Alergol       Date:  2021-10-01       Impact factor: 1.664

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.